We tested 4T1 cancer cells, which are resistant to anti-PD-1/anti-PD-L1 antibody therapy [24], and found that they did not respond to mJX-594 monotherapy at a high dose, but nevertheless exhibited an increase of intratumoral CD8+ T cells (by 6.7-fold) following mJX-594 treatment (Figure 2E and Supplementary Figure S2). This evidence concerns the gene PDCD1 and cancer.